Michael Lassmann
A German medical physicist who has led the physics section of Würzburg's nuclear medicine department for three decades and helped set the international standards used to calculate radiation doses from radioactive cancer treatments.
Overview
Michael Lassmann has worked as a medical physics expert in the Department of Nuclear Medicine at University Hospital Würzburg since 1988, was appointed head of the department's physics section in 1994, and holds a full professorship on the university's medical faculty. Between 2001 and 2008 he chaired the EANM Dosimetry Committee and continues to serve as a senior advisor to it; in 2017 he received the SNMMI Loevinger-Berman Award, nuclear medicine's leading dosimetry prize.
His research spans internal dosimetry for peptide receptor radionuclide therapy and radioiodine therapy, bone-marrow dosimetry methods, and biodosimetry for radiation protection. He is a co-author of the EANM/SNMMI joint procedure guideline for 177Lu-labelled PSMA-targeted radioligand therapy and of the PSMA-I&T theranostic first-in-human studies, and has continued this line of work through his successor Johannes Tran-Gia's Heisenberg professorship in multimodal imaging and theranostics at Würzburg.
| Title | Journal | Year |
|---|---|---|
| Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT) | European Journal of Nuclear Medicine and Molecular Imaging | 2023 |
| 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies | Journal of Nuclear Medicine | 2015 |
Similar pages
not linked directly; found by shared links- PersonDale L. Bailey
Shares Radioligand dosimetry, Lutetium-177 and the tags physics, dosimetry.
- Key paperEANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands
Shares Lutetium-177 radioligand therapy, Radioligand dosimetry, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 and the tag dosimetry.
- IdeaTerbium-161 instead of lutetium-177 in the same ligands
Shares Lutetium-177 radioligand therapy, Radioligand dosimetry, Peptide receptor radionuclide therapy (PRRT), Lutetium-177.
- TechnologyMonte Carlo dosimetry
Shares Radioligand dosimetry, Lutetium-177 and the tags physics, dosimetry.
- TechnologySPECT dosimetry workflow for radionuclide therapy
Shares Lutetium-177 radioligand therapy, Radioligand dosimetry, Peptide receptor radionuclide therapy (PRRT), Lutetium-177 and the tag dosimetry.
- CollectionOpenDose
Shares Lutetium-177 and the tags physics, dosimetry.
- Key paperResults and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms
Shares Richard P. Baum, Radioligand dosimetry, Peptide receptor radionuclide therapy (PRRT), Lutetium-177.
- InstitutionCuranosticum Wiesbaden-Frankfurt